Bone Marrow Transplantation Combined with Mesenchymal Stem Cells Induces Immune Tolerance without Cytotoxic Conditioning

Wang, Yunchuan; Liu, Jiaqi; Xu, Chengfeng; Zhang, Wanfu; Li, Bai; Li, Na; Yang, Liu; Wang, Yaojun; Su, Yingjun; Hu, Dahai

doi:10.1016/j.jss.2011.06.020

Cited by 9 publications

(6 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, a protocol that induced mixed chimerism with no cytotoxic conditioning was evaluated. 101 Wang et al 101 established mixed chimerism by IBM--BMT combined with BM-derived allogeneic MSC treatment in mice. IBM-BMT is a method that administers donor BM directly into the recipient BM.…”

Section: Induction Of Mixed Chimerism Using Mscsmentioning

confidence: 99%

The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation

Kim¹,

Kim

Cho

2013

Exp Mol Med

View full text Add to dashboard Cite

In the last 10 years, mesenchymal stem cells (MSCs) have emerged as a therapeutic approach to regenerative medicine, cancer, autoimmune diseases, and many more due to their potential to differentiate into various tissues, to repair damaged tissues and organs, and also for their immunomodulatory properties. Findings in vitro and in vivo have demonstrated immune regulatory function of MSCs and have facilitated their application in clinical trials, such as those of autoimmune diseases and chronic inflammatory diseases. There has been an increasing interest in the role of MSCs in allogeneic hematopoietic stem cell transplantation (HSCT), including hematopoietic stem cell engraftment and the prevention and treatment of graft-versus-host disease (GVHD), and their therapeutic potential has been reported in numerous clinical trials. Although the safety of clinical application of MSCs is established, further modifications to improve their efficacy are required. In this review, we summarize advances in the potential use of MSCs in HSCT. In addition, we discuss their use in clinical trials of the treatment of GVHD following HSCT, the immunomodulatory capacity of MSCs, and their regenerative and therapeutic potential in the field of HSCT.

show abstract

Section: Induction Of Mixed Chimerism Using Mscsmentioning

confidence: 99%

The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation

Kim¹,

Kim

Cho

2013

Exp Mol Med

View full text Add to dashboard Cite

show abstract

“…Co-administration of allogeneic hematopoietic stem cells and third-party myeloid progenitor (MP) transplantation simultaneously with placement of a MP-matched skin graft demonstrated that the organ donor matched Treg was not essential for tolerance but MP did [41] . Donor specific immune tolerance could be effectively induced by intra-bone marrow-bone marrow transplantation combined with BMSCs treatment without any additional cytoreductive recipient treatment, which provided a promising allograft transplantation strategy whenever the donor bone marrow was available [42] . Moreover, thirdparty BMSCs transplantation could prolong skin graft survival time by inhibiting T lymphocyte activation and proliferation [43] .…”

Section: Necrosismentioning

confidence: 99%

New advances in the mesenchymal stem cells therapy against skin flaps necrosis

Zhang¹

2014

WJSC

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs), multipotential cells that reside within the bone marrow, can be induced to differentiate into various cells, such as osteoblasts, adipocytes, chondrocytes, vascular endothelial progenitor cells, and other cell types. MSCs are being widely studied as potential cell therapy agents due to their angiogenic properties, which have been well established by in vitro and in vivo researches. Within this context, MSCs therapy appears to hold substantial promise, particularly in the treatment of conditions involving skin grafts, pedicle flaps, as well as free flaps described in literatures. The purpose of this review is to report the new advances and mechanisms underlying MSCs therapy against skin flaps necrosis.

show abstract

“…13–15 Unlike whole organ transplantation or many other allogeneic cell transplants, mesenchymal stem cell transplants do not appear to cause rejection and instead may be associated with evidence of induced tolerance to the donor. 16, 17 …”

mentioning

confidence: 99%

Mesenchymal Precursor Cells as Adjunctive Therapy in Recipients of Contemporary Left Ventricular Assist Devices

et al. 2014

View full text Add to dashboard Cite

Background Allogeneic mesenchymal precursor cells (MPC) injected during left ventricular assist device (LVAD) implantation may contribute to myocardial recovery. This trial explores the safety and efficacy of this strategy. Methods and Results In this multi-center, double-blind, sham-procedure controlled trial, 30 patients were randomized (2:1) to intramyocardial injection of 25M MPCs or medium during LVAD implantation. The primary safety endpoint was incidence of infectious myocarditis, myocardial rupture, neoplasm, hypersensitivity reaction, and immune sensitization (90 days post-randomization). Key efficacy endpoints were functional status and ventricular function, while temporarily weaned from LVAD support (90 days post-randomization). Patients were followed until transplant or 12 months post-randomization, whichever came first. Mean age was 57.4 (±13.6) years, mean LVEF 18.1%, and 66.7% were destination therapy LVADs. No safety events were observed. Successful temporary LVAD weaning was achieved in 50% of MPC and 20% of control patients at 90 days (p=0.24); the posterior probability that MPCs increased the likelihood of successful weaning is 93%. At 90 days, 3 deaths occurred in control and none in MPC patients. Mean LVEF following successful wean was 24.0% (MPC=10) and 22.5% (Control=2) (p=0.56). At 12 months, 30% of MPC and 40% of control patients were successfully temporarily weaned from LVAD support (p=0.69) and 6 deaths occurred in MPC patients. Donor-specific HLA sensitization developed in 2 MPC and 3 control patients and resolved by 12 months. Conclusions In this preliminary trial, administration of MPCs appeared to be safe and there was a potential signal of efficacy. Future studies will evaluate the potential for higher or additional doses to enhance the ability to wean LVAD recipients off support. Clinical Trial Registration Information ClinicalTrials.gov. Identifier: NCT01442129.

show abstract

Bone Marrow Transplantation Combined with Mesenchymal Stem Cells Induces Immune Tolerance without Cytotoxic Conditioning

Cited by 9 publications

References 45 publications

The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation

The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation

New advances in the mesenchymal stem cells therapy against skin flaps necrosis

Mesenchymal Precursor Cells as Adjunctive Therapy in Recipients of Contemporary Left Ventricular Assist Devices

Contact Info

Product

Resources

About